Methylprednisolone, intravenous immunoglobulin, tocilizimab or anakinra for children with Paediatric Inflammatory Multisystem Syndrome temporally associated with SARS CoV-2 (PIMS-TS, MIS-C) – report from a randomised, controlled, open-label, platform trial

Bibliographic Details
Main Authors:	Haynes, R, Landray, M, Staplin, N, Spata, E, Peto, L, Knight, M, Mafham, M, Emberson, J, Horby, P
Other Authors:	RECOVERY Collaborative Group
Format:	Journal article
Language:	English
Published:	Elsevier 2023

Comparison of methylprednisolone alone versus intravenous immunoglobulin plus methylprednisolone for multisystem inflammatory syndrome in children (MIS-C)
by: Dien Minh Tran, et al.
Published: (2025-03-01)

Multisystem Inflammatory Syndrome in an Adult (MIS-A) Successfully Treated with Anakinra and Glucocorticoids
by: Paolo Cattaneo, et al.
Published: (2021-06-01)

Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
by: Mafham, M, et al.
Published: (2021)

Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
by: Landray, M, et al.
Published: (2022)

Multicenter Randomized Trial of Methylprednisolone vs. Intravenous Immunoglobulins to Treat the Pediatric Inflammatory Multisystem Syndrome—Temporally Associated With SARS-CoV-2 (PIMS-TS): Protocol of the Swissped RECOVERY Trial
by: Tatjana Welzel, et al.
Published: (2022-05-01)

30 Multisystem inflammatory syndrome in children (MIS-C/PIMS): an overview
by: Eunice Jia Lin Tang
Published: (2021-04-01)

Anakinra treatment in multisystemic inflammatory syndrome in children (MIS-C) associated with COVID-19
by: Şengül Çaǧlayan, et al.
Published: (2022-08-01)

Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
by: Horby, P, et al.
Published: (2021)

COVID-19-Associated Paediatric Inflammatory Multisystem Syndrome (PIMS-TS) in Intensive Care: A Retrospective Cohort Trial (PIMS-TS INT)
by: Tereza Musilová, et al.
Published: (2023-02-01)

Allocated but not treated: the silent 16% – Authors' reply
by: Horby, P, et al.
Published: (2022)

Hemolytic anemia following intravenous immunoglobulins in children with PIMS-TS: Two case reports
by: E. Sedlin, et al.
Published: (2023-04-01)

Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis
by: RECOVERY Collaborative Group, et al.
Published: (2022)

Higher dose corticosteroids in patients admitted to hospital with COVID-19 who are hypoxic but not requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial
by: Horby, PW, et al.
Published: (2023)

Paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS): a Brazilian cohort
by: André Cavalcanti, et al.
Published: (2022-02-01)

Cardiac assessment and inflammatory markers in children with paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV2 (PIMS-TS) treated with methylprednisolone versus intravenous immunoglobulins: 6-month follow-up outcomes of the randomised controlled Swissped RECOVERY trialResearch in context
by: Maya C. Andre, et al.
Published: (2024-01-01)

Subcutaneous anakinra in the management of refractory MIS-C in France
by: Perrine Dusser, et al.
Published: (2024-02-01)

Immunomodulatory therapy in children with paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS, MIS-C; RECOVERY): a randomised, controlled, open-label, platform trial
by: RECOVERY Collaborative Group
Published: (2024)

Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
by: Horby, PW, et al.
Published: (2021)

Dexamethasone in hospitalized patients with Covid-19 — preliminary report
by: Horby, P, et al.
Published: (2020)

Dimethyl fumarate in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
by: Horby, P, et al.
Published: (2024)

Use of Continuous Intravenous Anakinra Infusion in Multisystem Inflammatory Syndrome in Children
by: Abdulaziz Alolayan, et al.
Published: (2023-01-01)

Pediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS) in the United Kingdom and Ireland: What is new?
by: Pier Paolo Bassareo
Published: (2021-04-01)

Swissped-RECOVERY: masked independent adjudication for the interpretation of non-randomised treatment in a two-arm open-label randomised controlled trial (methylprednisolone vs immunoglobulins) in Paediatric Inflammatory Multisystem Syndrome Temporally Associated with SARS-CoV-2 (PIMS-TS) involving 10 secondary and tertiary paediatric hospitals in Switzerland
by: Andrew Atkinson, et al.
Published: (2024-04-01)

Paediatric multisystem inflammatory syndrome temporally associated with SARS-CoV-2 (PIMS-TS): Prospective, national surveillance, United Kingdom and Ireland, 2020
by: Jessica Flood, et al.
Published: (2021-04-01)

Case Report: Use of Anakinra in Multisystem Inflammatory Syndrome During COVID-19 Pandemic
by: Sara Della Paolera, et al.
Published: (2021-02-01)

A retrospective comparative analysis of factors affecting the decision and outcome of initial intravenous immunoglobulin alone or intravenous immunoglobulin plus methylprednisolone use in children with the multisystem inflammatory syndrome
by: İlker Devrim, et al.
Published: (2022-08-01)

Effect of hydroxychloroquine in hospitalized patients with COVID-19
by: Horby, P, et al.
Published: (2020)

A national consensus management pathway for Paediatric Inflammatory Multisystem Syndrome - Temporally associated with SARS-CoV-2 (PIMS-TS): The results of a national Delphi process
by: Harwood, R, et al.
Published: (2020)

Outcomes of MIS-C patients treated with anakinra: a retrospective multicenter national study
by: Francesco Licciardi, et al.
Published: (2023-08-01)

Multisystem inflammatory syndrome in children (MIS-C) and “Near MIS-C”: A continuum?
by: Sarah Khafaja, et al.
Published: (2023-01-01)

Long-term treatment with anakinra and canakinumab resolves patellar subchondral erosion in neonatal-onset multisystem inflammatory disease
by: A. Leone, et al.
Published: (2019-04-01)

Early recognition of PIMS-TS: a single centre retrospective review
by: Roshni Mistry, et al.
Published: (2021-10-01)

Neuro-PIMS-TS: a single case report and review of the literature
by: Antonio Scarcella, et al.
Published: (2022-12-01)

Acute Vision Loss and Conjunctival Hemorrhage as Telltale Symptoms of PIMS-TS
by: Houda Nassih PhD, et al.
Published: (2022-07-01)

Effectiveness of early Anakinra on cardiac function in children with multisystem inflammatory syndrome of COVID-19: a systematic review
by: Muhammed Shabil, et al.
Published: (2024-08-01)

Cardiac involvement in children with paediatric multisystem inflammatory syndrome temporally associated with SARS-CoV-2 (PIMS-TS): data from a prospective nationwide surveillance study
by: Anita Uka, et al.
Published: (2023-10-01)

Clinical outcomes and safety of anakinra in the treatment of multisystem inflammatory syndrome in children: a single center observational study
by: Brian L.P. Dizon, et al.
Published: (2023-07-01)

Multisystem inflammatory syndrome associated with coronavirus disease 2019: MIS-C-concepts and MIS-concepts
by: Pradeep Kumar Sharma
Published: (2021-01-01)

Multisystem inflammatory syndrome in children (MIS-C) and long Covid
by: Yonca Bulut
Published: (2024-03-01)

Evidence for the prevention and treatment of stroke in dialysis patients
by: Herrington, W, et al.
Published: (2014)

Methylprednisolone, intravenous immunoglobulin, tocilizimab or anakinra for children with Paediatric Inflammatory Multisystem Syndrome temporally associated with SARS CoV-2 (PIMS-TS, MIS-C) – report from a randomised, controlled, open-label, platform trial

Similar Items

Similar Items